Lovastatin for the adjunctive treatment of schizophrenia: A preliminary randomized double-blind placebo-controlled trial
Ahmad Ghanizadeh, Zahra Rezaee, Sara Dehbozorgi, Michael Berk, Shahin Akhondzadeh
PSYCHIATRY RESEARCH | ELSEVIER IRELAND LTD | Published : 2014
While statins target many of the pathways to neuroprogression in schizophrenia, the safety and efficacy of statins for treating schizophrenia has never been examined. This is an 8-week randomized double blind controlled clinical trial examining the efficacy and safety of adjunctive lovastatin (20 mg/day) treatment or placebo for people with schizophrenia. The baseline characteristics of the two groups were not different. Endpoint changes in Positive and Negative Syndrome Scale (PANSS) total and subscale scores did not differ between the two groups. However there was a significant difference between the doses of risperidone used in the two groups. The mean dose in the lovastatin and placebo g..View full abstract
Awarded by Shiraz University of Medical Sciences
Awarded by NHMRC
This study was supported by a grant (no: 2715) from Shiraz University of Medical Sciences to Prof. Ahmad Ghanizadeh. This study was Dr. Rezaei's postgraduate thesis toward the Iranian Board of Psychiatry. MB is supported by a NHMRC Senior Principal Research Fellowship 1059660.